Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)

Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV-A Memphis 37b Strain)

This study is to evaluate the antiviral effect of GS-5806 in healthy adults infected with a strain of Respiratory Syncytial Virus.

Inclusion Criteria:

• Healthy male or female
• Between 18 to 45 years old
• Body Mass Index of 18 to 33 kg/m2

Exclusion Criteria:

• Acute or chronic medical illness
• Positive for Human Immunodeficiency Virus, Hepatitis B or C
• Nose or nasopharynx abnormalities
• Abnormal lung function